<DOC>
	<DOCNO>NCT00335322</DOCNO>
	<brief_summary>In treatment naïve HIV infected subject , combination antiretroviral therapy include efavirenz combine tenofovir emtricitabine offer non-inferior antiretroviral efficacy 48 week , compare either atazanavir boost ritonavir combine tenofovir emtricitabine tenofovir emtricitabine combine zidovudine abacavir , assess change baseline plasma HIV-1 RNA viral load .</brief_summary>
	<brief_title>ALTAIR - Alternative Antiretroviral Strategies : Comparison Three Initial Regimens</brief_title>
	<detailed_description>The primary objective study compare virological efficacy , measure time-weighted mean change baseline plasma HIV-RNA , safety , three strategic regimens initial antiretroviral therapy ( ART ) contain fix dose formulation tenofovir emtricitabine , either efavirenz ritonavir boost atazanavir zidovudine plus abacavir . ( Primary comparison regimen I versus II I versus III describe ) . I. tenofovir ( TDF ) + emtricitabine ( FTC ) + efavirenz ( EFV ) II . tenofovir ( TDF ) + emtricitabine ( FTC ) + ritonavir/atazanavir ( r/ATV ) III . tenofovir ( TDF ) + emtricitabine ( FTC ) + zidovudine ( ZDV ) + abacavir ( ABC ) Secondary objective study undertake range analysis include limited following , 1 . Percentage patient &lt; 50 copy HIV RNA/mL ( &lt; 400 copies/mL ) week 48 week 96 treatment arm . 2 . Time confirm ( first two consecutive ) plasma HIV-1 RNA &lt; 50 copies/mL ( &lt; 400 copies/mL ) treatment arm . 3 . Time virologic failure define confirmed plasma HIV-1 RNA &gt; 50 copies/mL ( 400 copies/mL ) confirm &lt; 50 copies/mL ( time = 0 patient never achieve plasma virus load &lt; 50 &lt; 400 copies/mL ) . 4 . Mean change baseline absolute CD4+ T cell count week 48 96 treatment arm . 5 . Time change randomly assign therapy ( reason individually aggregate ) treatment arm . 6 . Time first virologic failure ( defined # 3 ) cessation randomly assign antiretroviral therapy . 7 . Mean change baseline Lipodystrophy Case Definition score week 48 96 treatment arm . 8 . Mean change baseline peripheral central adipose tissue , measure CT DEXA week 48 96 treatment arm . 9 . Mean change baseline fast lipid glycemic parameter week 48 96 treatment arm . 10 . Comparison total number patient serious adverse event ( SAEs ) , cumulative incidence SAEs , treatment arm . 11 . Comparison total number patient adverse event ( AEs ) , cumulative incidence AEs , associate cessation randomly assign therapy treatment arm . 12 . Patterns genotypic HIV resistance associate virological treatment failure across treatment arm . 13 . Describe aspects immune reconstitution disease . 14 . Adherence therapy association virologic outcomes treatment arm . 15 . Comparison quality life treatment arm . Following result schedule week 48 data analysis , protocol steer committee amend study protocol follow : - Patients Arms I II remain current study drug - Patients Arm III may switch physician 's discretion either Arm I II - There protocol amendment include one extra follow visit week 144 patient , regardless treatment arm current treatment - All patient encourage stay study week 144 , maximize follow study .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>HIV1 positive license diagnostic test presume duration infection &gt; 6 month date randomisation . Aged &gt; 16 year age ( minimum age determine local regulation legal requirement dictate ) . Antiretroviral treatment naïve . Qualifying plasma HIV RNA &gt; 2,000 copies/mL CD4+ T cell count ≥ 50 cells/µL . No evidence harbour drug resistant HIV ( base upon genotypic drug test ) . Calculated creatinine clearance ( CLCr ) great equal 70 mL/min ( CockcroftGault formula ) . Able provide write informed consent . The following laboratory variable , absolute neutrophil count ( ANC ) &lt; 750 cells/µL haemoglobin &lt; 8.0 g/dL platelet count &lt; 50,000 cells/µL serum AST , ALT &gt; 5 x upper limit normal ( ULN ) serum bilirubin &gt; 1.5 x ULN Pregnant nursing mother . Current use human growth hormone , testosterone anabolic steroid . Current use prohibit medication describe product specific information . Acute therapy serious infection serious medical illness ( judgement site Principal Investigator ) require systemic treatment and/or hospitalisation . Patients current alcohol illicit substance use opinion site Principal Investigator would conflict aspect conduct trial . Patients unlikely able remain followup protocoldefined period . Patients know renal insufficiency . Patients obstructive liver disease . Patients intractable diarrhoea ( six loose stools/day least seven consecutive day ) . History acute chronic pancreatitis . Presence cardiomyopathy ( due cause ) significant cardiovascular disease , unstable ischemic heart disease . Prisoners subject compulsorily detain ( involuntarily incarcerate ) .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Human Immunodeficiency Virus ( HIV )</keyword>
</DOC>